/PRNewswire/ Universal Diagnostics (UDX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced.
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
20/04/2021 - 5 minutes
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market.
Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics in the US, and Somatex in Germany this year alone.
This is just one example of the many financial transactions happening in the diagnostics market over the past few months, with major deals, increasing stock prices, and unprecedented revenues.
(0) Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today promising new data for its investigational blood-based lung cancer test. The data, presented at the IASLC 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC20), held virtually 28
th-31
st January 2021, used methylation status measurement of the tumour-derived portion from cell-free DNA (cfDNA) in plasma for patient classification. Results of the study show the potential of the test to detect different lung cancer sub-types early, with high sensitivity and specificity, and indicate the potential of using blood-based screening for wider population regardless of the smoking-status of the patient.